Meeting
2023 ASCO Annual Meeting
Phase 1 trial of GD2-SADA:177Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma.
Authors
Taofeek K. Owonikoko
UPMC Hillman Cancer Center, Pittsburgh, PA
Taofeek K. Owonikoko , Justin C Moser , Janet Yoon , Emily K Slotkin , Afshin Dowlati , Vincent T Ma , Maria Düring , Joen Sveistrup
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Radiopharmaceuticals
Clinical Trial Registration Number
NCT05130255
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3162)
DOI
10.1200/JCO.2023.41.16_suppl.TPS3162
Abstract #
TPS3162
Poster Bd #
355b
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors.
First Author: Hatem Hussein Soliman
Poster
2011 ASCO Annual Meeting
Phase I study of irinotecan and temsirolimus in patients with refractory sarcomas.
First Author: S. Movva
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1 trial of navitoclax and sorafenib in patients with refractory solid tumors with a hepatocellular carcinoma expansion cohort.
First Author: Oluwadunni Eunice Emiloju
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.
First Author: Anthony W. Tolcher